EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Theravance Biopharma's Enterprise Value is $395.18 Mil.
Theravance Biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.92 Mil. Therefore, Theravance Biopharma's EV-to-EBIT for today is -8.42.
The historical rank and industry rank for Theravance Biopharma's EV-to-EBIT or its related term are showing as below:
TBPH'
s EV-to-EBIT Range Over the Past 10 Years
Min: -10.32 Med: -5.59 Max: -0.74
Current: -8.42
During the past 12 years, the highest EV-to-EBIT of Theravance Biopharma was -0.74. The lowest was -10.32. And the median was -5.59.
TBPH's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs TBPH: -8.42
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Theravance Biopharma's Enterprise Value for the quarter that ended in Dec. 2023 was $487.28 Mil.
Theravance Biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.92 Mil. Theravance Biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9.63%.
Theravance Biopharma EV-to-EBIT Historical Data
The historical data trend for Theravance Biopharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theravance Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma EV-to-EBIT Distribution
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's EV-to-EBIT falls into.
Theravance Biopharma EV-to-EBIT Calculation
Theravance Biopharma's EV-to-EBIT for today is calculated as:
Theravance Biopharma's current Enterprise Value is $395.18 Mil.
Theravance Biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Theravance Biopharma's Enterprise Value for the quarter that ended in Dec. 2023 was $487.28 Mil.
Theravance Biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Theravance Biopharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Theravance Biopharma (Theravance Biopharma) Business Description
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TBPH has been successfully added to your 